New drug cocktail takes on bulky head and neck tumors
NCT ID NCT07041788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to a special type of radiation and standard chemotherapy can help people with advanced, bulky head and neck cancer live longer without the disease getting worse. The study will enroll 25 adults who have not had prior treatment. Participants will receive the drug combination along with radiation, followed by maintenance therapy. The main goal is to see if this approach improves the 2-year event-free survival rate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (immunotherapy drugs) combined with chemotherapy (docetaxel, cisplatin) and spatially fractionated radiotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option that improves long-term control of advanced head and neck cancer.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The treatment involves strong drugs and radiation, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?